The rising prevalence in GLP-1 agonists for metabolic conditions has generated a debate about delivery methods : skin-applied devices versus tablets . Usually , GLP-1 therapies were solely available in https://aoifeyfwf469349.jaiblogs.com/68005443/glp-1-skin-applications-vs-oral-medications-what-best-for-individuals